Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 20/20 | 0.94 |
| ▸ | PLK1 | P53350 | 6/20 | 0.94 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.94 |
| ▸ | GAK | O14976 | 1/20 | 0.94 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.94 |
| ▸ | JAK2 | O60674 | 1/20 | 0.94 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.94 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.94 |
| ▸ | PAK4 | O96013 | 1/20 | 0.94 |
| ▸ | ABL1 | P00519 | 1/20 | 0.94 |
| ▸ | LCK | P06239 | 1/20 | 0.94 |
| ▸ | FYN | P06241 | 1/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.94 |
| ▸ | WEE2 | P0C1S8 | 1/20 | 0.94 |
| ▸ | BCR | P11274 | 1/20 | 0.94 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.94 |
| ▸ | SYK | P43405 | 1/20 | 0.94 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.94 |
| ▸ | NEK2 | P51955 | 1/20 | 0.94 |
| ▸ | NEK3 | P51956 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adavosertib SCHEMBL29381006 | 0.97 | WEE1 (1.00) | WEE1PLK1PKMYT1GAKEPHB6 | |
| Adavosertib SCHEMBL30559444 | 0.97 | WEE1 (1.00) | WEE1PLK1PKMYT1GAKEPHB6 | |
| Adavosertib SCHEMBL1504444 | 0.97 | WEE1 (1.00) | WEE1PLK1PKMYT1GAKEPHB6 | |
| Adavosertib SCHEMBL1504998 | 0.96 | WEE1 (0.98) | WEE1PLK1PKMYT1GAKEPHB6 | |
| Adavosertib SCHEMBL1504996 | 0.96 | WEE1 (0.98) | WEE1PLK1PKMYT1GAKEPHB6 | |
| SCHEMBL25890930 | 0.95 | WEE1 (0.96) | WEE1PLK1PKMYT1GAKEPHB6 | |
| Adavosertib SCHEMBL3579242 | 0.94 | WEE1 (0.94) | WEE1PLK1PKMYT1GAKEPHB6 | |
| SCHEMBL18797921 | 0.94 | WEE1 (0.87) | WEE1PLK1PKMYT1GAKEPHB6 | |
| SCHEMBL12622218 | 0.93 | WEE1 (0.82) | WEE1PLK1PKMYT1GAKEPHB6 | |
| SCHEMBL1813967 | 0.91 | WEE1 (0.89) | WEE1PLK1PKMYT1GAKEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2017278-B1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD KK (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD KK (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8791125-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | SAGARA TAKESHI | 2011-08-04 | — | — | US | disclosed |
| US-7935708-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7834019-B2 | Substituted pyrazolo[3,4-d]pyrimidinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-7834019-B2 | Substituted pyrazolo[3,4-d]pyrimidinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-7834019-B2 | Substituted pyrazolo[3,4-d]pyrimidinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | MERCK SHARP & DOHME LLC | 2010-03-11 | — | — | US | disclosed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | WEE1 1/4885PLK1 749/4885PKMYT1 852/4885 |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | WEE1, WEE2, GRK3 | WEE1 1/4885PLK1 749/4885PKMYT1 852/4885 |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | WEE1, WEE2, GRK3 | WEE1 1/4885PLK1 749/4885PKMYT1 852/4885 |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | WEE1 1/4885PLK1 749/4885PKMYT1 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.